In order to investigate the relationship between known prognostic factors, BCL-2 mRNA levels, RiBi rate and disease outcome, we profiled an exploratory cohort of 83 DLBCL patients treated with anthracycline-based first-line chemoimmunotherapy (cohort 1, see STAR Methods), with T-GEP (for the assessment of the COO, and measurement of BCL-2 and MYC mRNA levels) and with silver staining of histological sections to determine the nucleolar area. This evidence concerns the gene MYC and diffuse large B-cell lymphoma.